CERUS CORP
Close on Oct 19, 2026
- Market cap
- $445.25M
- P/E (TTM)
- –
- Dividend yield
- –
About Cerus
Surgical & Medical Instruments & Apparatus, SIC 3841
Cerus Corporation is a biomedical company focused on the field of blood transfusion safety. The company develops and commercializes the INTERCEPT Blood System, which is designed to reduce the risk of transfusion-transmitted infections by targeting and inactivating pathogens such as viruses, bacteria, and parasites in donated blood components. Its commercial product line includes systems for platelets, plasma, and cryoprecipitation, while a pathogen reduction system for red blood cells remains in development. The company’s primary customers and end users include blood centers, hospitals, clinicians, and governmental entities such as the Biomedical Advanced Research and Development Authority and the United States Department of Defense.
Cerus operates primarily in the United States and international markets, including Europe, the Middle East, and other regions, with direct operations and customer relationships spanning countries such as France, the Netherlands, and China. The company maintains its principal executive offices in Concord, California.
Summary of the business section of Cerus's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CERUS CORP
- Founded
- 1991
- Headquarters
- Concord, CA
- Address
- 1220 Concord Avenue, Suite 600 94520
- Phone
- (925) 288-6000
- Website
- www.cerus.com
- Employees
- 275, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Francisco, California
Stock & identifiers
- Ticker
- CERS
- Exchange
- Nasdaq
- IPO date
- Jan 31, 1997
- Shares outstanding
- 202M, Jul 16, 2026
- Public float
- $230.00M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1020214
- CUSIP
- 157085101
- ISIN
- US1570851014
- LEI
- 254900BIEY9XIDA04Q21
- EIN
- 68-0262011
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| William Mariner Greenman | President and CEO, Director | 5,154,955 |
| Chrystal Jensen | Chief Legal Officer | 936,657 |
| Vivek K. Jayaraman | Chief Executive Officer | 2,232,211 |
| Kevin Dennis Green | Chief Financial Officer | 1,062,188 |
| Richard J. Benjamin | Chief Medical Officer | 777,361 |
| Eric Bjerkholt | Director | 261,679 |
| Dean A. Gregory | Director | 146,725 |
| Frank Witney | Director | 340,059 |
| Jami K. Nachtsheim | Director | 268,362 |
| Ann Lucena | Director | 232,284 |
| Hua Shan | Director | 192,386 |
| Timothy L. Moore | Director | 205,073 |
| Daniel N. Swisher JR | Director | 207,045 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 William M. Greenman | $3.79M | $5.77M | $1.77M | $30 | $68 |
| FY2024 William M. Greenman | $2.98M | $2.06M | $1.25M | $22 | $76 |
| FY2023 William M. Greenman | $3.66M | $760.32K | $1.48M | $31 | $83 |
| FY2022 William M. Greenman | $5.26M | $120.29K | $1.95M | $53 | $79 |
| FY2021 William M. Greenman | $5.18M | $5.13M | $1.97M | $98 | $120 |
| FY2020 William M. Greenman | $4.52M | $7.51M | $1.58M | $164 | $125 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 275 employees company-wide.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 29, 2021 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 5, 2019 | Deregistration | Termination of SEC registration (Form 15) |
| Apr 30, 2013 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 30, 2010 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 31, 1997 | IPO | Initial public offering priced (424B4 prospectus) |